Longitudinal insights into the natural history of Type 2 diabetes among Koreans: A 20‐year community‐based prospective cohort study
Journal of Internal Medicine · 2025
DOI: 10.1111/joim.70010 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Wonsuk Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, South Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Prediabetic State. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Centers for Disease Control and Prevention, National Research Foundation of Korea.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To investigate the natural history of diabetes mellitus (DM) based on metabolic phenotypes of prediabetes in a community‐based prospective study.
Methods
Individuals aged 40–69 years without DM were followed for 20 years. Glycemic parameters, including the 75 g oral glucose tolerance test, were assessed at baseline and biennially thereafter. Markov models were used to estimate each glycemic state's annual transition probabilities and average total length of residence.
Results
Among the 7,676 participants without DM, 205 had isolated impaired fasting glucose (iIFG), and 1,753 had impaired glucose tolerance (IGT) at baseline. During the 17.5 years of follow‐up, 2,313 (30.1%) cases of DM occurred. The annual transition to DM for those with iIFG was 7.7% (95% confidence interval [CI] 6.9, 8.5) and 6.9% (95% CI 6.6, 7.3) for those with IGT. In the normoglycemia ↔ iIFG → DM model, the total length in normoglycemia was 49.4 years (95% CI 47.0, 52.1), and the length in iIFG was 6.3 years (95% CI 5.9, 6.8). In the normoglycemia ↔ IGT → DM model, the total length in normoglycemia was 34.0 years (95% CI 32.4, 35.4), and the length in IGT was 11.9 years (95% CI 11.1, 12.5).
Conclusions
Individuals remained normoglycemic for long periods. However, the progression to DM occurs rapidly once prediabetes develops, regardless of the metabolic phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, South Korea.
- Department of Biological Chemistry, University of California Irvine, Irvine, California, USA.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
- Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.
- Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Public Health Foundation of India, New Delhi, India.
Förderung
- Korea Centers for Disease Control and Prevention
- National Research Foundation of Korea
Zitieren
APA
Choi, W., Moon, J. H., Choe, H. J., Chang, H. H., Kondal, D., Narayan, K. M. V., & Cho, N. H. (2025). Longitudinal insights into the natural history of Type 2 diabetes among Koreans: A 20‐year community‐based prospective cohort study. Journal of Internal Medicine. https://doi.org/10.1111/joim.70010
Vancouver
Choi W, Moon JH, Choe HJ, Chang HH, Kondal D, Narayan KMV, et al. Longitudinal insights into the natural history of Type 2 diabetes among Koreans: A 20‐year community‐based prospective cohort study. Journal of Internal Medicine. 2025. doi:10.1111/joim.70010
BibTeX
@article{Choi2025,
author = {Choi, Wonsuk and Moon, Joon Ho and Choe, Hun Jee and Chang, Howard H and Kondal, Dimple and Narayan, K M Venkat and Cho, Nam H},
title = {Longitudinal insights into the natural history of Type 2 diabetes among Koreans: A 20‐year community‐based prospective cohort study},
journal = {Journal of Internal Medicine},
year = {2025},
doi = {10.1111/joim.70010}
}
EUVIMED